# Editas Medicine

transitioned in December 2024 from ex-vivo CRISPR-Cas12a (reni-cel, discontinued) to in-vivo gene editing; lead candidate EDIT-401 upregulates LDLR and cut LDL-C, Lp(a) and ApoB by ~90% in non-human primates, IND/CTA targeted for mid-2026.


Source: https://en.bioecon.ru/companies/editas-medicine/
Updated: 2026-07-29

- Country: United States

## Technologies

- [Genome editing](https://en.bioecon.ru/technology/genome-editing/)